GEn1E Lifesciences

Gen1E Lifesciences is a pre-clinical stage biopharmaceutical company focused on transforming research in areas with unmet medical needs into therapies. Ge1E targets those therapies with commercial and technical attractiveness. Criteria that they look for include therapies that have huge unmet need, low competition, clear reimbursement and intellectual property, predictable animal data, objective clinical end point with a biomarker, qualify for FDAFDA fast track, tax credit and marketing exclusivity.

Gen1E also has an exclusive option with UMB for its p38a KinaseKinase inhibitor for treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome and various inflammatory and age-related diseases.